December 26th 2023
Fred Locke, MD shares his perspective on the future treatment paradigm in large B-cell lymphoma, emphasizing CAR-T cells, allogeneic strategies, bispecifics, toxicity management, and treatment sequencing.
Expert discusses the emergence of recently approved bispecific antibodies in R/R LBCL, emphasizing the importance of toxicity management for adverse events such as cytokine release syndrome (CRS).
December 19th 2023
A comprehensive overview of clinical and patient factors that impact disease progression beyond CAR T-cell therapy in lymphoma.
Gain insights into treatment outcomes of CAR T, highlighting lisocabtagene maraleucel and the TRANSCEND NHL 001 study for R/R LBCL.
December 12th 2023
A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.
Expert perspective on treatment sequencing strategies for patients with LBCL.
December 5th 2023
Dr. Locke reviews the latest data from ZUMA-7 and TRANSFORM studies, evaluating CAR T in the second line setting for R/R LBCL.
Fred Locke, MD, provides an overview of transplant eligibility for patients with large B-cell lymphoma, highlighting second line strategies with CAR T-cell therapy and bispecific antibodies.
August 11th 2022
Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.
A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.
August 8th 2022
The panelists share their approach to the treatment and work-up of patients who require salvage therapy.
Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.
July 28th 2022
Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.
Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.
July 22nd 2022
Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.
Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.
July 18th 2022
Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.
The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.
July 7th 2022
Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.
Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.